We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+17.14%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$51.5M
Cap. Flow
+$10.4M
Cap. Flow %
2.97%
Top 10 Hldgs %
68.11%
Holding
35
New
7
Increased
16
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
LH icon
Labcorp
LH
+$10.1M
2
SRCL
Stericycle Inc
SRCL
+$7.66M
3
HOLX
Hologic
HOLX
+$7.07M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5.78M
5
MDRX
Veradigm Inc. Common Stock
MDRX
+$4.76M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$18.5M
2
XRAY icon
Dentsply Sirona
XRAY
+$12M
3
MDT icon
Medtronic
MDT
+$5.92M
4
VSI
Vitamin Shoppe Inc.
VSI
+$3.35M
5
SIEN
Sientra, Inc.
SIEN
+$2.44M

Sector Composition

Rank Sector Weight
1 Healthcare 88.33%
2 Industrials 6.2%
3 Consumer Discretionary 2.7%
4 Communication Services 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVA
1
DELISTED
NuVasive, Inc.
NUVA
$37.4M 10.68%
525,000
+25,000
+5% +$1.59M
NVCR icon
2
NovoCure
NVCR
$1.73B
$33.4M 9.54%
635,000
-465,000
-42% -$18.5M
LH icon
3
Labcorp
LH
$25B
$27.8M 7.93%
186,240
+66,348
+55% +$10.1M
MDRX
4
DELISTED
Veradigm Inc. Common Stock
MDRX
$26.4M 7.55%
1,950,000
+350,000
+22% +$4.76M
MDT icon
5
Medtronic
MDT
$109B
$25.6M 7.3%
260,000
-64,000
-20% -$5.92M
SRCL
6
DELISTED
Stericycle Inc
SRCL
$21.7M 6.2%
370,000
+120,000
+48% +$7.66M
BIO icon
7
Bio-Rad Laboratories Class A
BIO
$8.71B
$20.3M 5.81%
65,000
+10,000
+18% +$3.1M
NXTM
8
DELISTED
NxStage Medical Inc.
NXTM
$16.7M 4.78%
600,000
+129,463
+28% +$3.64M
RIGL icon
9
Rigel Pharmaceuticals
RIGL
$681M
$14.6M 4.17%
455,000
+192,500
+73% +$5.78M
LNTH icon
10
Lantheus
LNTH
$6.49B
$14.5M 4.14%
970,000
+185,381
+24% +$2.71M
HOLX
11
DELISTED
Hologic
HOLX
$14.3M 4.1%
350,000
+175,000
+100% +$7.07M
CORI
12
DELISTED
Corium International, Inc.
CORI
$13.6M 3.87%
1,425,000
+60,721
+4% +$523K
GILD icon
13
Gilead Sciences
GILD
$162B
$13.5M 3.86%
175,000
-25,000
-13% -$1.89M
OPTN
14
DELISTED
OptiNose
OPTN
$10.7M 3.05%
57,333
+15,666
+38% +$4.47M
ATRC icon
15
AtriCure
ATRC
$1.92B
$9.63M 2.75%
275,000
+15,000
+6% +$475K
SCI icon
16
Service Corp International
SCI
$11.7B
$9.45M 2.7%
213,856
+20,330
+11% +$821K
CORV
17
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$8.28M 2.36%
2,060,000
+60,000
+3% +$265K
PCRX icon
18
Pacira BioSciences
PCRX
$1.04B
$7.37M 2.11%
150,000
-40,000
-21% -$1.73M
VSI
19
DELISTED
Vitamin Shoppe Inc.
VSI
$6M 1.71%
600,000
-325,000
-35% -$3.35M
HIND
20
Vyome Holdings
HIND
$14.9M
– –
0
– –
GKOS icon
21
Glaukos
GKOS
$9.83B
$4.87M 1.39%
+75,000
New +$3.68M
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.36M 0.67%
1,000,000
+75,000
+8% +$187K
STRM
23
DELISTED
Streamline Health Solutions
STRM
$2.24M 0.64%
126,667
+48,514
+62% +$927K
MODN
24
DELISTED
MODEL N, INC.
MODN
$1.58M 0.45%
+100,000
New +$1.75M
ALKS icon
25
CALL
Alkermes
ALKS
$8.22B
$696K 0.2%
+2,000
New +$86.8K
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q3 2018 Portfolio in Review

As of Q3 2018, Tamarack Advisers held 35 positions worth $350M, up 17% from $299M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Tamarack Advisers's Q3 2018 filing shows 7 new, 16 increased, 6 reduced and 5 closed positions. Its largest new stake was Glaukos: 75,000 shares worth $4.87M. The largest sale was NovoCure, an estimated $18.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Industrials and Consumer Discretionary.

  • Tamarack Advisers's largest Q3 2018 buy was Glaukos: 75,000 shares worth $4.87M.
  • Tamarack Advisers added most to Labcorp in Q3 2018, an estimated $10.1M increase.
  • Tamarack Advisers's biggest Q3 2018 reduction was NovoCure, cutting an estimated $18.5M.
  • Tamarack Advisers fully exited Dentsply Sirona in Q3 2018, selling an estimated $12M.
  • Tamarack Advisers's ten largest holdings make up 68% of its $350M portfolio in Q3 2018.
  • Tamarack Advisers opened 7 new positions and closed 5 in Q3 2018.
  • Tamarack Advisers's portfolio value rose 17% quarter-over-quarter to $350M.

Based on Tamarack Advisers's 13F filing for Q3 2018, filed 13 Nov 2018.